Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6083614rdf:typepubmed:Citationlld:pubmed
pubmed-article:6083614lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:6083614lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:6083614lifeskim:mentionsumls-concept:C1414431lld:lifeskim
pubmed-article:6083614lifeskim:mentionsumls-concept:C0007200lld:lifeskim
pubmed-article:6083614lifeskim:mentionsumls-concept:C0205267lld:lifeskim
pubmed-article:6083614lifeskim:mentionsumls-concept:C0205171lld:lifeskim
pubmed-article:6083614pubmed:issue5lld:pubmed
pubmed-article:6083614pubmed:dateCreated1985-2-5lld:pubmed
pubmed-article:6083614pubmed:abstractTextSince intermittent cardioplegic reperfusion during an ischemic period may reduce the ischemic stress of the heart at least by lowering myocardial temperature, we compared the post-ischemic recovery of the dog heart following cardioplegia and subsequent continuous ischemia of 1 X 300 minutes at 22 +/- 1 degree C (model 1) and following cardioplegia and subsequent 3 X 100 minutes of ischemia at 17 +/- 1 degree C with intermittent 4-minute cardioplegic reperfusion every 100 minutes (model 2). The parameters of post-ischemic recovery were the cardiac O2 consumption per beat at work (MVO2-E0): HR), the stability of cardiac rhythm, the left ventricular content of high-energy phosphates, and ultrastructure. Solution HTK with a magnesium concentration of 9 mM/L, in clinical use up to the beginning of 1984, resulted in a significantly better post-ischemic recovery in model 1, despite about 40% lesser ischemic stress in model 2. A reduction of Mg concentration from 9 to 4 mM/l, as in the HTK solution clinically tested since February 1984, did facilitate the post-ischemic recovery in model 1 as indicated by the stability of cardiac rhythm but led to a significant improvement of all parameters of recovery in model 2. Moreover, recovery in model 2 after reduced Mg was also clearly better than in model 1 corresponding to the lesser ischemic stress. The parameters myocardial O2 consumption (MVO2) and potassium loss during HTK perfusion containing 9 and 4 mM/l, respectively, gave indications of specific membrane labilizing effects of Mg in the cardioplegic solution HTK.lld:pubmed
pubmed-article:6083614pubmed:languageenglld:pubmed
pubmed-article:6083614pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6083614pubmed:citationSubsetIMlld:pubmed
pubmed-article:6083614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6083614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6083614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6083614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6083614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6083614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6083614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6083614pubmed:statusMEDLINElld:pubmed
pubmed-article:6083614pubmed:monthOctlld:pubmed
pubmed-article:6083614pubmed:issn0171-6425lld:pubmed
pubmed-article:6083614pubmed:authorpubmed-author:GebhardM MMMlld:pubmed
pubmed-article:6083614pubmed:authorpubmed-author:PreusseC JCJlld:pubmed
pubmed-article:6083614pubmed:authorpubmed-author:Bretschneider...lld:pubmed
pubmed-article:6083614pubmed:authorpubmed-author:SchnabelP APAlld:pubmed
pubmed-article:6083614pubmed:issnTypePrintlld:pubmed
pubmed-article:6083614pubmed:volume32lld:pubmed
pubmed-article:6083614pubmed:ownerNLMlld:pubmed
pubmed-article:6083614pubmed:authorsCompleteYlld:pubmed
pubmed-article:6083614pubmed:pagination271-6lld:pubmed
pubmed-article:6083614pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:meshHeadingpubmed-meshheading:6083614-...lld:pubmed
pubmed-article:6083614pubmed:year1984lld:pubmed
pubmed-article:6083614pubmed:articleTitleDifferent effects of cardioplegic solution HTK during single or intermittent administration.lld:pubmed
pubmed-article:6083614pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6083614pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed